Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy
| Autor: | Jorge Luis Poo Ramírez, Claudia Isabel Blanco Vela |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Liver Cirrhosis
Ornithine medicine.medical_specialty Cirrhosis Hepatic coma Glutamine Administration Oral Specialties of internal medicine L-ornithine L-aspartate Severity of Illness Index Gastroenterology Cerebral edema chemistry.chemical_compound Liver disease Ammonia Internal medicine Humans Hyperammonemia Urea Medicine Hepatic encephalopathy Hepatology business.industry Dipeptides General Medicine medicine.disease Treatment Outcome Endocrinology chemistry RC581-951 Urea cycle Quality of Life business |
| Zdroj: | Annals of Hepatology, Vol 10, Iss, Pp S55-S59 (2011) |
| ISSN: | 1665-2681 |
| Popis: | Hyperammonemia and associated cerebral edema cause neurological abnormalities in liver disease patients. Although only 15% of ammonia production originates in the colon, management strategies for hepatic encephalopathy (HE) have focused on reducing ammonia generation from the bowel rather than on manipulating systemic mechanisms involved in ammonia metabolism. Administration of L-ornithine L-aspartate (LOLA) improves mental status and decreases serum and spinal fluid ammonia levels by stimulating both the urea cycle and glutamine (Gln) synthesis, which are key metabolic pathways in ammonia detoxification. LOLA was shown to be superior to a placebo for management of HE, and the results of several clinical trials suggest that its effectiveness could be higher with the more severe grades of this syndrome. Compared with the standard treatment, LOLA is effective not only in reducing hyperammonemia and the severity of this disease, but also in improving the patient's perceived quality of life. Therefore, LOLA is a promising alternative for the management of HE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|